Please login to the form below

Not currently logged in
Email:
Password:

New UCB CEO Jean-Christophe Tellier expands his executive team

Hands new roles to Emmanuel Caeymaex, Bharat Tewarie and Jeff Wren
Jean-Christophe Tellier

The new CEO of UCB Jean-Christophe Tellier has added new members to his executive committee team, with the changes being effective from next month.

Tellier, who replaced Roch Doliveux on January 1, joined the company in 2011 and aided the establishment and growth of Cimzia, Vimpat and Neuprol, now UCB's leading medicines.

The new additions to the team, effective from February 1, will be Emmanuel Caeymaex, Bharat Tewarie and Jeff Wren.

Caeymaex joined UCB in 1994, subsequently had a stint as president of UCB Japan from 2006 to 2011, and takes on the position of immunology patient value unit head.

Tewarie has been appointed chief marketing officer. He is a trained medical doctor and has 27 tears of experience in the pharma and biotech industries, will specific knowledge in domains such as immunology and neurology.

Meanwhile Wren, who joined the firm in 2010 and has been senior VP of UCB North America, takes up the role of neurology patient value unit head.
Tellier will also restructure UCB's executive committee into the following four areas:

Patient Value UnitsNew medicines, neurology, immunology, bone disorders
Patient Value PracticesStrategic marketing, development and medical
Patient Value OperationsGeographic operations, established brands, technical operations and business development
Patient Value FunctionsFinance, talent and company reputation, legal

Ismail Kola and Iris Loew Friedrich will work on Patient Value Units, Mark McDade will be in Patient Value Operations and Patient Value Functions will be formed of Detlef Thielgen, Fabrice Enderlin and Anna Richo.

Commenting on UCB's new leadership structure, Tellier said: “UCB's leadership team has done a tremendous job in transforming the company into a global science leader, helping patients with severe diseases enjoy more normal lives.

“It is important for UCB to ensure leadership continuity while adding expertise in our focus areas of neurology and immunology to accelerate momentum as we head into our next period of growth.”

Tellier replaced Roch Doliveux, who stepped down on December 31 after leading UCB for 10 years. He remains an honorary member of the board and honorary chairman of its executive committee.

14th January 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics